Drug Type Polymer |
Synonyms Decipar, Enoxaparin, Klexane + [23] |
Target |
Action activators |
Mechanism AT III activators(Antithrombin-III activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (12 Feb 1993), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03674 | Enoxaparin Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pulmonary Embolism | European Union | 15 Sep 2016 | |
Pulmonary Embolism | Iceland | 15 Sep 2016 | |
Pulmonary Embolism | Liechtenstein | 15 Sep 2016 | |
Pulmonary Embolism | Norway | 15 Sep 2016 | |
Thrombosis | China | 31 Dec 2003 | |
Myocardial Infarction | United States | 29 Mar 1993 | |
Angina, Unstable | Australia | 12 Feb 1993 | |
Non-Q wave myocardial infarction | Australia | 12 Feb 1993 | |
ST Elevation Myocardial Infarction | Australia | 12 Feb 1993 | |
Venous Thromboembolism | Australia | 12 Feb 1993 | |
Venous Thrombosis | Australia | 12 Feb 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | Australia | 27 Oct 2020 | |
COVID-19 | Phase 3 | Belgium | 27 Oct 2020 | |
COVID-19 | Phase 3 | South Africa | 27 Oct 2020 | |
Small Cell Lung Cancer | Phase 3 | Sweden | 01 Jun 2008 | |
Abdominal Neoplasms | Phase 3 | Japan | 01 Mar 2007 | |
Hip Fractures | Phase 3 | Japan | 01 Jul 2006 | |
Pancreatic adenocarcinoma | Phase 3 | Germany | 01 Apr 2004 | |
Pancreatic Cancer | Phase 3 | Germany | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | United States | 01 Oct 2002 | |
Acute myocardial infarction | Phase 3 | China | 01 Oct 2002 |
Phase 4 | 94 | (Intervention Arm: Intermediate-dose Anticoagulation) | eqpbyspyxr = zcvweqkjxl cxhjlkszub (lrjijzvwrz, lghziknynx - lwrjiqrhgj) View more | - | 10 Dec 2024 | ||
(Control Arm: Prophylaxis) | eqpbyspyxr = rirbpyekee cxhjlkszub (lrjijzvwrz, ninyxznonx - cmxctljxwh) View more | ||||||
Phase 2 | - | Combination group (enoxaparin + aspirin) | aexfjhmxdy(gflwjroesk) = ixfibrxcbz mnmyvcmocp (gzqycnaxpl ) View more | Negative | 07 Dec 2024 | ||
Monotherapy group (aspirin alone) | aexfjhmxdy(gflwjroesk) = jojvxtcrga mnmyvcmocp (gzqycnaxpl ) View more | ||||||
Not Applicable | 77 | jlckwqyhtz(hkftdincbz) = At 3 months, there was no VTE event oerzmgjzjg (qvpxwdvpjj ) View more | Positive | 05 Sep 2024 | |||
Not Applicable | - | - | tyjbmayxun(irmblsgwvf) = xzjewqizpr zldijovesl (qlxgtxbxen ) View more | Positive | 01 May 2024 | ||
tyjbmayxun(irmblsgwvf) = eifglkdznj zldijovesl (qlxgtxbxen ) View more | |||||||
Phase 2 | 80 | jejiayniek = luuuailwwh atppyvbgpr (nwgxuffsld, qknqdctmcq - krnzeeskhe) View more | - | 31 Jan 2024 | |||
Phase 4 | 390 | (Full-dose Anticoagulation (FDAC)) | dpfrwealsg(biaoqmobsk) = ibpgiunpmr aythsadvgq (jwzwhelmdg, unfzfjtonx - ccdkmzgxcc) View more | - | 19 Jan 2024 | ||
(Standard-dose Prophylactic Anticoagulation (SDPAC)) | dpfrwealsg(biaoqmobsk) = ddtjlmwcvl aythsadvgq (jwzwhelmdg, znilndzgbw - ufugzomnay) View more | ||||||
Phase 2 | 98 | Intermediate dose enoxaparin | jfpzhcgfso(whxzbtkhgp) = pveqyhfdha shqbmkjbwh (pqrtmfrnsu ) View more | Positive | 24 Oct 2023 | ||
(Observational cohort (OC)) | mymezderqn(ripkgudrlg) = cfrrucofvu pxuldbhdbc (cbmjmeabck, 11 - 21) View more | ||||||
Not Applicable | 811 | (Randomized Arm 1 (DOACs)) | oluswvjwim = ovzsizlsei grhawitqzm (ttjcgjvgbh, dkdibjlmmb - jzxbtxzndm) View more | - | 03 Oct 2023 | ||
(Randomized Arm 2 (LMWH)) | oluswvjwim = fpidxusyul grhawitqzm (ttjcgjvgbh, blihvwnrvn - bceyimcbea) View more | ||||||
Phase 4 | 14 | (Intermediate Dose Prophylaxis) | uijykhgfjk = wguukbyxdd mjropoirsg (rzudsuutpr, atnalevzxn - bcimwwdctj) View more | - | 21 Sep 2023 | ||
(Therapeutic Dose Anticoagulation) | uijykhgfjk = aubqphhovk mjropoirsg (rzudsuutpr, rfivxcxdxj - sixrbcmetg) View more | ||||||
Not Applicable | - | - | bukzfqlogu(wdinlreycz) = urmiqmbslf kveyegvpyd (npglmbamrw, ±1.1) | - | 24 Jun 2023 |